Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U004 - Rheumatology for the Dermatologist: Evaluating the Rheumatology Patient in the Dermatology Clinic

Friday, February 16; 7:30 AM - 8:30 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Define the relationship between cutaneous and systemic lupus, describe dermatomyositis as defined by autoantibody profiles, distinguish inflammatory and non-inflammatory arthritis.
  • Appropriately order and interpret autoimmune serologic testing.
  • Develop a helpful review of systems to approach systemic rheumatologic disease.

Description

We will review the relationship between cutaneous lupus subsets and systemic lupus as well as current understanding of prognostic implications of CLE with regard to systemic disease. We will review dermatomyositis clinical findings (skin and systemic) as they relate to autoantibody profiles. We will review appropriate rheumatology review of systems and approach to inflammatory arthritis for the dermatologist. Other topics will include brief review of systemic sclerosis screening and monitoring.

Disclosures

  • Merola, Joseph, MD, MSc: AbbVie – A(H), SP(H); Amgen – A(H), I(NC); Biogen – C(Fees), I(Grants/Research Funding); Eli Lilly and Company – A(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H); Momenta Pharmaceuticals, Inc. – C(H); Novartis – A(H); Pfizer Inc. – I(NC);
  • Vleugels, Ruth Ann, MD: no financial relationships exist with commercial interests.
Schedule
Friday, February 16
7:30 AM
Dr. Merola / Clinical and Serologic Approaches to SLE/CLE
8:00 AM
Dr. Vleugels / Systemic Considerations in Dermatomyositis for the Dermatologist
Event Details
  • Date
    Friday, February 16
  • Time
    7:30 AM - 8:30 AM
  • Location
    Room 23C
  • CME Credits
    1.00
  • Type
Directors/Co-Directors
  • Joseph Merola, MD, MSc, FAAD
Speakers
  • Ruth Ann Vleugels, MD, FAAD